Calliditas Therapeutics AB ADR (CALT): Price and Financial Metrics

Calliditas Therapeutics AB ADR (CALT): $19.00

1.53 (-7.45%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add CALT to Watchlist
Sign Up

CALT Price/Volume Stats

Current price $19.00 52-week high $29.30
Prev. close $20.53 52-week low $15.25
Day low $19.00 Volume 11,700
Day high $19.80 Avg. volume 8,259
50-day MA $21.42 Dividend yield N/A
200-day MA $19.41 Market Cap 566.01M

CALT Stock Price Chart Interactive Chart >


Calliditas Therapeutics AB ADR (CALT) Company Bio


Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product candidate Nefecon intended for treatment of patients with the inflammatory renal disease IgA nephropathy. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.


CALT Latest News Stream


Event/Time News Detail
Loading, please wait...

CALT Latest Social Stream


Loading social stream, please wait...

View Full CALT Social Stream

Latest CALT News From Around the Web

Below are the latest news stories about CALLIDITAS THERAPEUTICS AB that investors may wish to consider to help them evaluate CALT as an investment opportunity.

Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital

Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed and fully drawn a term loan of 92 million Euros with funds managed by Athyrium Capital Management, LP ("Athyrium"). Proceeds from the loan will primarily be utilized for full repayment of the company's existing 68 million Euro loan with Kreos Capital.

Yahoo | December 27, 2023

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the U.S. Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. TARPEYO was first approved in December 2021 under accelerated approval, based on the surrogate marker of proteinuria. Marking a significant milestone, TARPEYO is

Yahoo | December 20, 2023

Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 18/100,396 entitled "New Pharmaceutical Compositions." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.

Yahoo | December 11, 2023

Calliditas announces additions to the management team

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the company has added a new member to its management team, Head of Technical Operations Lars Stubberud. Additionally, the company is welcoming Brian Gorman as its new Group General Counsel. These changes will take effect on 1 January 2024.

Yahoo | December 1, 2023

Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced the initiation of a Phase 2 clinical study to evaluate setanaxib in Alport syndrome.

Yahoo | November 30, 2023

Read More 'CALT' Stories Here

CALT Price Returns

1-mo -15.37%
3-mo -24.00%
6-mo 11.37%
1-year -23.23%
3-year -29.50%
5-year N/A
YTD -26.20%
2023 51.44%
2022 -31.34%
2021 -26.35%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!